CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...